{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:53:05Z","timestamp":1790419985590,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.antiviral.2018.07.020","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T13:41:46Z","timestamp":1533390106000},"page":"103-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Comparison of antiviral resistance across acute and chronic viral infections"],"prefix":"10.1016","volume":"158","author":[{"given":"Stephen","family":"Mason","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Devincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5582-5785","authenticated-orcid":false,"given":"Stephen","family":"Toovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim Z.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.07.020_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/INF.0000000000001533","article-title":"Effectiveness of palivizumab in high-risk infants and children","volume":"36","author":"Anderson","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2018.07.020_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2018.07.020_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cmi.2016.02.007","article-title":"Virological surveillance of influenza and other respiratory viruses during six consecutive seasons from 2006 to 2012 in Catalonia, Spain","volume":"22","author":"Anton","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2018.07.020_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00591-12","article-title":"Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors","author":"Asahchop","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.020_bib5","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMc0910060","article-title":"Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis","volume":"361","author":"Baz","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/infdis\/159.3.430","article-title":"Resistance of influenza a virus to amantadine and rimantadine: results of one decade of surveillance","volume":"159","author":"Belshe","year":"1989","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib7","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants","volume":"368","author":"Blanken","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib8","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.07.020_bib9","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.07.020_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004065","article-title":"Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses","volume":"10","author":"Butler","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.07.020_bib11","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.020_bib12","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v22.i1.145","article-title":"Overview of hepatitis B virus mutations and their implications in the management of infection","author":"Caligiuri","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/387183a0","article-title":"Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection","volume":"387","author":"Chun","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.07.020_bib14","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.07.020_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/science.7824947","article-title":"HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy","volume":"267","author":"Coffin","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.07.020_bib16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-119-8-199310150-00003","article-title":"Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection","volume":"119","author":"Collier","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib17","series-title":"Fields Virology","first-page":"1086","article-title":"Respiratory syncytial virus and metapneumovirus","author":"Collins","year":"2013"},{"key":"10.1016\/j.antiviral.2018.07.020_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1006\/viro.1998.9462","article-title":"Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein","volume":"252","author":"Crowe","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.07.020_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1849","article-title":"Current treatment of hepatitis B virus infections","author":"De Clercq","year":"2015","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2010.04.011","article-title":"Antiretroviral drugs","author":"De Clercq","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.07.020_bib22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1203\/01.PDR.0000145255.86117.6A","article-title":"Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load","volume":"56","author":"DeVincenzo","year":"2004","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.antiviral.2018.07.020_bib24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1086\/423213","article-title":"Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants","volume":"190","author":"DeVincenzo","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0928-0197(98)00032-4","article-title":"Quasispecies and the implications for virus persistence and escape","volume":"10","author":"Domingo","year":"1998","journal-title":"Clin. Diagn. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib26","doi-asserted-by":"crossref","first-page":"958s","DOI":"10.1093\/jn\/127.5.958S","article-title":"Rapid evolution of viral RNA genomes","volume":"127","author":"Domingo","year":"1997","journal-title":"J. Nutr."},{"key":"10.1016\/j.antiviral.2018.07.020_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.micro.51.1.151","article-title":"RNA virus mutations and fitness for survival","volume":"51","author":"Domingo","year":"1997","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib28","article-title":"Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.07.020_bib29","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/genetics\/148.4.1667","article-title":"Rates of spontaneous mutation","volume":"148","author":"Drake","year":"1998","journal-title":"Genetics"},{"key":"10.1016\/j.antiviral.2018.07.020_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(14)70821-7","article-title":"Antiviral combinations for severe influenza","author":"Dunning","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1086\/421779","article-title":"Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation","volume":"39","author":"El Saleeby","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib32","unstructured":"EMEA, n.d. Guideline on the clinical evaluation of direct acting 6 antivirals for the treatment of chronic hepatitis. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2016\/07\/WC500209917.pdf."},{"key":"10.1016\/j.antiviral.2018.07.020_bib33","series-title":"Annals of Internal Medicine","first-page":"654","article-title":"Immunopathogenic mechanisms of HIV infection","author":"Fauci","year":"1996"},{"key":"10.1016\/j.antiviral.2018.07.020_bib34","unstructured":"FDA, n.d. Guidance for Industry Antiviral Product Development \u2014 Conducting and Submitting Virology Studies to the Agency [WWW Document]. https:\/\/www.fda.gov\/ohrms\/dockets\/98fr\/05d-0183-gdl0002-01.pdf."},{"key":"10.1016\/j.antiviral.2018.07.020_bib35","unstructured":"FDA, n.d. Guidance for Industry Influenza: Developing Drugs for Treatment and\/or Prophylaxis. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm091219.pdf."},{"key":"10.1016\/j.antiviral.2018.07.020_bib36","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/ajt.12209","article-title":"Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C","volume":"13","author":"Fontana","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.07.020_bib37","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.R110.129809","article-title":"Influenza hemagglutinin and neuraminidase membrane glycoproteins","author":"Gamblin","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.07.020_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2016.07.014","article-title":"HCV NS5A replication complex inhibitors","author":"Gao","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1574887108666131213120354","article-title":"Efficacy and safety of sofosbuvir in the treatment of chronic hepatitis C: the dawn of a new era","volume":"9","author":"Gentile","year":"2014","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.antiviral.2018.07.020_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.cld.2011.05.010","article-title":"The NS5A replication complex inhibitors: difference makers?","author":"Gish","year":"2011","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib41","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.coviro.2012.08.004","article-title":"The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance","volume":"2","author":"G\u00f6tte","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","author":"Group","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.antiviral.2018.07.020_bib43","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less","volume":"337","author":"Hammer","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3201\/eid1502.081031","article-title":"Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08","volume":"15","author":"Hauge","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib46","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1128\/AAC.35.9.1741","article-title":"Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine","volume":"35","author":"Hayden","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.07.020_bib47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.antiviral.2007.08.007","article-title":"Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China","volume":"77","author":"He","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.020_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.07.020_bib49","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.7041255","article-title":"Rapid evolution of RNA genomes","volume":"215","author":"Holland","year":"1982","journal-title":"Science (80-. )"},{"key":"10.1016\/j.antiviral.2018.07.020_bib50","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0168-8278(96)80115-2","article-title":"Serum HCV RNA levels assessed by quantitative NASBA\u00ae: stability of viral load over time, and lack of correlation with liver disease","volume":"25","author":"Hollingsworth","year":"1996","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coviro.2014.04.009","article-title":"The epidemiology and spread of drug resistant human influenza viruses","volume":"8","author":"Hurt","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib52","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1099\/0022-1317-69-10-2623","article-title":"The fusion glycoproteins of human respiratory syncytial virus of subgroups a and B\u202f: sequence conservation provides a structural basis for antigenic relatedness","volume":"69","author":"Johnson","year":"1988","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0042-6822(86)90378-8","article-title":"Influenza B virus PB1 protein: nucleotide sequence of the genome RNA segment predicts a high degree of structural homology with the corresponding influenza A virus polymerase protein","volume":"152","author":"Kemdirim","year":"1986","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.07.020_bib54","first-page":"192","article-title":"The 2014\u20132015 national impact of the 2014 american academy of pediatrics guidance for respiratory syncytial virus immunoprophylaxis on preterm infants born in the United States","volume":"1","author":"Kong","year":"2017","journal-title":"Am. J. Perinatol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib55","series-title":"Fields Virology","first-page":"1561","article-title":"HIV-1:Pathogenesis, clinical manifestations, and treatment","author":"Kuritzkes","year":"2013"},{"key":"10.1016\/j.antiviral.2018.07.020_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0163089","article-title":"An intranasal Proteosome-adjuvanted trivalent influenza vaccine is safe, immunogenic & efficacious in the human viral influenza challenge model. Serum IgG & mucosal IgA are important correlates of protection against illness associated with infection","volume":"11","author":"Lambkin-Williams","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.07.020_bib57","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1099\/0022-1317-75-5-951","article-title":"Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase","volume":"75","author":"Larder","year":"1994","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib58","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.2479983","article-title":"Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)","volume":"246","author":"Larder","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.07.020_bib59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.virol.2017.07.017","article-title":"Deep sequencing of RSV from an adult challenge study and from naturally infected infants reveals heterogeneous diversification dynamics","volume":"510","author":"Lau","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.07.020_bib60","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrmicro3003","article-title":"The role of mutational robustness in RNA virus evolution","volume":"11","author":"Lauring","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib61","first-page":"381","article-title":"Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course","volume":"7","author":"Lee","year":"1994","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.07.020_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/v7092850","article-title":"Clinical implications of antiviral resistance in influenza","author":"Li","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.07.020_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28025","article-title":"Present and future therapies of hepatitis B: from discovery to cure","author":"Liang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.07.020_bib64","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/jvi.69.8.5087-5094.1995","article-title":"Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase","volume":"69","author":"Mansky","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7326\/0003-4819-155-4-201108160-00358","article-title":"Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda","volume":"155","author":"Mills","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12985-017-0728-2","article-title":"Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence","volume":"14","author":"Omura","year":"2017","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.07.020_bib67","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-immunol-051116-052206","article-title":"Protective and harmful immunity to RSV infection","volume":"35","author":"Openshaw","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib68","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/0042-6822(74)90458-9","article-title":"Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA)","volume":"59","author":"Palese","year":"1974","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.07.020_bib69","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0042-6822(74)90276-1","article-title":"Characterization of temperature sensitive influenza virus mutants defective in neuraminidase","volume":"61","author":"Palese","year":"1974","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.07.020_bib70","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3201\/eid1801.110515","article-title":"Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006\u20132010","volume":"18","author":"Papenburg","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib71","first-page":"1","article-title":"Modelling hepatitis C therapy-predicting effects of treatment","volume":"0","author":"Perelson","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib72","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"Perelson","year":"1996","journal-title":"Science (80-. )"},{"key":"10.1016\/j.antiviral.2018.07.020_bib73","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/JCM.43.5.2356-2362.2005","article-title":"Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus","volume":"43","author":"Perkins","year":"2005","journal-title":"J. Clin. Microbiol."},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2018.07.020_bib74","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/00002030-199311002-00014","article-title":"Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction","volume":"7","author":"Piatak","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2018.07.020_bib75","first-page":"10651","article-title":"The H275Y neuraminidase mutation of the pandemic a\/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells","volume":"86","author":"Pinilla","year":"2012","journal-title":"Potentially Compromising Fitness Ferrets"},{"key":"10.1016\/j.antiviral.2018.07.020_bib76","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.R500020200","article-title":"The M2 proton channels of influenza A and B viruses","author":"Pinto","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.07.020_bib77","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"Powdrill","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.07.020_bib78","doi-asserted-by":"crossref","first-page":"15992","DOI":"10.3748\/wjg.v20.i43.15992","article-title":"Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy","volume":"20","author":"Preciado","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000103","article-title":"Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir","volume":"4","author":"Rameix-Welti","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.07.020_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002881","article-title":"Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate","volume":"8","author":"Ribeiro","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.07.020_bib81","doi-asserted-by":"crossref","first-page":"29621","DOI":"10.1074\/jbc.270.50.29621","article-title":"Development of drug resistance to HIV-1 protease inhibitors","volume":"270","author":"Ridky","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.07.020_bib82","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/jac\/dkw078","article-title":"Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression","volume":"71","author":"Rojas","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.07.020_bib83","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/jac\/dkw011","article-title":"Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients","volume":"71","author":"Rokx","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.07.020_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib85","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1128\/JCM.02659-13","article-title":"Emergence of an oseltamivir-resistant influenza A\/H3N2 Virus in an elderly patient receiving a suboptimal dose of antiviral prophylaxis","volume":"51","author":"Roussy","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib86","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00090-16","article-title":"The human immune response to respiratory syncytial virus infection","volume":"30","author":"Russell","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.07.020_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002685","article-title":"From molecular genetics to phylodynamics: evolutionary relevance of mutation rates across viruses","volume":"8","author":"Sanju\u00e1n","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.07.020_bib88","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1128\/JVI.00694-10","article-title":"Viral mutation rates","volume":"84","author":"Sanju\u00e1n","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib89","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature06531","article-title":"Structure and mechanism of the M2 proton channel of influenza A virus","volume":"451","author":"Schnell","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.07.020_bib90","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF01311091","article-title":"Evolution of influenza polymerase: nucleotide sequence of the PB2 gene of A\/Chile\/1\/83 (H1N1)","volume":"103","author":"Schreier","year":"1988","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib91","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.1128\/jvi.70.10.6617-6624.1996","article-title":"Evolution of a persistent aphthovirus in cytolytic infections: partial reversion of phenotypic traits accompanied by genetic diversification","volume":"70","author":"Sevilla","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib92","doi-asserted-by":"crossref","first-page":"10489","DOI":"10.1128\/JVI.73.12.10489-10502.1999","article-title":"Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection","volume":"73","author":"Shankarappa","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib93","series-title":"Fields Virology","first-page":"1151","article-title":"Orthomyxoviridae","author":"Shaw","year":"2013"},{"key":"10.1016\/j.antiviral.2018.07.020_bib94","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"Shen","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib95","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/molbev\/msm103","article-title":"The genesis and spread of reassortment human influenza A\/H3N2 viruses conferring adamantane resistance","volume":"24","author":"Simonsen","year":"2007","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib96","doi-asserted-by":"crossref","first-page":"11247","DOI":"10.1128\/JVI.01657-16","article-title":"Deep sequencing of influenza a virus from a human challenge study reveals a selective bottleneck and only limited intrahost genetic diversification","volume":"90","author":"Sobel Leonard","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib97","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00171-17","article-title":"Transmission bottleneck size estimation from pathogen deep-sequencing data, with an application to human influenza a virus","volume":"91","author":"Sobel Leonard","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib98","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1586\/14787210.2014.966083","article-title":"A review of neuraminidase inhibitor susceptibility in influenza strains","volume":"12","author":"Spanakis","year":"2014","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.antiviral.2018.07.020_bib99","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/596311","article-title":"Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children","volume":"48","author":"Stephenson","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051439","article-title":"Genetic variability among complete human respiratory syncytial virus subgroup a genomes: bridging molecular evolutionary dynamics and epidemiology","volume":"7","author":"Tan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.07.020_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.21664","article-title":"Viral load in patients infected with pandemic H1N1 2009 influenza A virus","volume":"82","author":"To","year":"2010","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib103","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0166-0934(98)00172-4","article-title":"HBV viral load within subpopulations of peripheral blood mononuclear cells in HBV infection using limiting dilution PCR","volume":"78","author":"Trippler","year":"1999","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.antiviral.2018.07.020_bib104","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2018.04.009","article-title":"Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses","volume":"154","author":"Tu","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.020_bib105","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/01.qai.0000209899.05126.e4","article-title":"The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes","volume":"41","author":"van de Vijver","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.07.020_bib106","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0969-2126(98)00075-6","article-title":"Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase","volume":"6","author":"Varghese","year":"1998","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2018.07.020_bib107","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00126334-200309011-00002","article-title":"HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors","volume":"34","author":"Wainberg","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.07.020_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.07.020_bib109","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.coviro.2012.08.008","article-title":"Clinical relevance of HCV antiviral drug resistance","volume":"2","author":"Welsch","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib110","first-page":"642","article-title":"2014 update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib111","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/cis1220","article-title":"Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the influenza resistance information study (IRIS)","volume":"56","author":"Whitley","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib112","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJM196909112811102","article-title":"Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man","volume":"281","author":"Wingfield","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.07.020_bib113","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/0042-6822(89)90615-6","article-title":"Comparison of the three large polymerase proteins of influenza A, B, and C viruses","volume":"171","author":"Yamashita","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.07.020_bib114","first-page":"27448044","article-title":"Prevailing genotype distribution and characteristics of human respiratory syncytial virus in northeastern China","volume":"89","author":"Zheng","year":"2016","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib115","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/jiq100","article-title":"Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab","volume":"203","author":"Zhu","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib116","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/infdis\/jir790","article-title":"Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab","volume":"205","author":"Zhu","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib117","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1086\/314994","article-title":"Low incidence of rimantadine resistance in field isolates of influenza A viruses","volume":"180","author":"Ziegler","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.07.020_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2016.01263","article-title":"Evolution and transmission of respiratory syncytial group A (RSV-A) viruses in Guangdong, China 2008-2015","volume":"7","author":"Zou","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2018.07.020_bib119","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2893.2007.00915.x","article-title":"Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?","author":"Zoulim","year":"2007","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2018.07.020_bib120","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218301219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218301219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:37Z","timestamp":1759062517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218301219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":120,"alternative-id":["S0166354218301219"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.020","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of antiviral resistance across acute and chronic viral infections","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}